September 1987
Volume 28, Issue 9
Free
Articles  |   September 1987
The dichotomy between herpes simplex virus type 1-induced ocular pathology and systemic immunity.
Investigative Ophthalmology & Visual Science September 1987, Vol.28, 1533-1540. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E E Metzger, J A Whittum-Hudson; The dichotomy between herpes simplex virus type 1-induced ocular pathology and systemic immunity.. Invest. Ophthalmol. Vis. Sci. 1987;28(9):1533-1540.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
This content is PDF only. Please click on the PDF icon to access.
Abstract

Herpes simplex virus Type 1 (HSV-1) was injected into the mouse eye by the intravitreal (into the vitreous chamber; VC) or translimbal (across the limbus into the anterior chamber; TxL) route. These routes were compared for ocular pathology and systemic immunity. After VC inoculation, the virus-injected eye developed a viral infection, with the majority of opposite, uninjected eyes remaining intact and free of virus over the 4 week period of observation. In contrast, following translimbal inoculation, the entire virus-injected eye developed infection and inflammation together with subsequent chorioretinitis in the opposite uninjected eye. Systemic immunity induced by VC or TxL virus inoculation was similar to the effects of anterior chamber (AC) inoculation of the same dose of HSV-1: T cell-mediated DTH responses were suppressed while levels of anti-HSV neutralizing antibody were enhanced, compared to subcutaneously primed positive control mice. These findings demonstrate that HSV-1-induced ocular pathology does not necessarily correlate directly with systemic immunity.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×